Compare US Global Jets ETF (JETS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Medpace Holdings Inc — how do they compare? US Global Jets ETF trades at $27.45 (market cap $878.48M), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 19.1× US Global Jets ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and Medpace Holdings Inc for 14 Days on average.
| JETS | MEDP | |
|---|---|---|
Market Cap | $878.48M | $16.82B |
Volume | 4,465,925 | 223,093 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $630.19 |
52-Week Low | $23.64 | $393.42 |
Typical Hold Time | 26 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The U.S. Global Jets ETF (JETS) is trading at $27.475, down 0.7% on the day, with a bearish technical signal from moving averages but a neutral reading from oscillators. Recent news highlights competitive pressure from aerospace and defense ETFs like ARKX and ITA, which have outperformed JETS, while rising jet fuel costs due to Middle East tensions pose headwinds for airline profitability. Key support is at $27, with resistance at $28.
The outlook for JETS is challenged by high fuel expenses and underperformance relative to defense-focused peers, though travel demand remains a potential catalyst. Risks include volatile oil prices and geopolitical uncertainty, while analyst sentiment is cautious given cost pressures and competitive ETF alternatives.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
